Meeting
2014 ASCO Annual Meeting
Phase II trial of cixutumumab in combination with temsirolimus in pediatric patients with recurrent or refractory sarcoma: A report from the Children’s Oncology Group.
Authors
Lars M. Wagner
University of Kentucky, Lexington, KY
Lars M. Wagner , Maryam Fouladi , Atif Ahmed , Mark D. Krailo , Brenda Weigel , Steven G. DuBois , Austin Doyle , Helen X. Chen , Susan Blaney
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT01614795
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 10066)
DOI
10.1200/jco.2014.32.15_suppl.10066
Abstract #
10066
Poster Bd #
367
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase 2 study to evaluate palbociclib in combination with irinotecan and temozolomide in pediatric patients with recurrent or refractory Ewing sarcoma.
First Author: Theodore Willis Laetsch
First Author: Stuart Cramer
Poster
2013 ASCO Annual Meeting
Randomized phase II trial of cixutumumab (CIX) alone or with cetuximab (CET) for refractory recurrent/metastatic squamous cancer of head and neck (R/M-SCCHN).
First Author: Bonnie S. Glisson
Poster
2023 ASCO Annual Meeting
PEPN1924, a phase 2 study of trastuzumab deruxtecan (DS-8201a, T-DXd) in adolescents and young adults with recurrent HER2+ osteosarcoma: A Children’s Oncology Group Pediatric Early-Phase Clinical Trial Network study.
First Author: Damon R. Reed